Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
168 hedge funds and large institutions have $3.65B invested in Apellis Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 51 increasing their positions, 60 reducing their positions, and 14 closing their positions.
164% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 14
135% more call options, than puts
Call options by funds: $16.3M | Put options by funds: $6.96M
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
95% more capital invested
Capital invested by funds: $1.87B → $3.65B (+$1.78B)
16% more funds holding
Funds holding: 145 → 168 (+23)
2.16% more ownership
Funds ownership: 82.2% → 84.36% (+2.2%)
15% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 60
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$51.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$36.9M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$13.7M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$12.7M |
| 5 |
Renaissance Technologies
New York
|
+$9.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$32.4M |
| 2 |
Millennium Management
New York
|
-$28.6M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$25.1M |
| 4 |
State Street
Boston,
Massachusetts
|
-$18.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.9M |
APLS Hedge Fund Activity: Q4 2020 in Review
168 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2020, worth a combined $3.65B — up 95% from $1.87B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new APLS positions and 14 closed out — a net gain of 23 holders — while 51 added to existing stakes and 60 trimmed.
The largest buyer was Vanguard Group, adding an estimated $51.8M. The largest seller was Citadel Advisors, cutting an estimated $32.4M.
- 168 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2020, up from 145 in Q3 2020.
- Funds reported $3.65B of Apellis Pharmaceuticals stock for Q4 2020, up 95% quarter-over-quarter.
- 37 funds opened new Apellis Pharmaceuticals positions in Q4 2020 and 14 closed out, a net change of +23 holders.
- The largest Apellis Pharmaceuticals buyer in Q4 2020 was Vanguard Group, an estimated $51.8M added.
- The largest Apellis Pharmaceuticals seller in Q4 2020 was Citadel Advisors, an estimated $32.4M sold.
Based on aggregated 13F filings for Q4 2020.